The Columbia River Oncology Program is a city-wide consortium of hospitals and physicians who are dedicated to a community-based clinical oncology program. In the short period of four years, we have established the groundwork that has allowed us to become an extremely successful CCOP. In order to further the development of our CCOP, we aim to: continue the organizational activities of CROP, assuring high levels of participation from investigators throughout the community; continue to increase accrual to therapeutic and cancer control protocols; continue to emphasize the high priority protocol selections of the National Cancer Institute and our research bases; maintain our data quality control program; maintain strong community-wide base of support, and to continue to involve primary care physicians in CROP activities and protocols. Several key factors have allowed the Columbia River Oncology Program to develop quickly. Our experienced CCOP investigators and staff have extensive clinical research credentials which pre-date the initiation of CROP and which have allowed us to exceed NCI basic accrual requirements; in 1988-89, our total accrual was 86.3 credits to therapeutic trials. The Portland area has community wide expertise in cancer control interventions and research. In addition, our location in Portland offers us access to a large, otherwise untapped patient population. We have an extremely strong base of support from the participating institutions which both considerably lowers the National Cancer Institute's cost per patient and assures the CCOP of continuity. These factors, combined with our demonstrated initiative and resources, promise to provide the NCI with a strong CCOP program that continues to develop its potential. In fact, our collaborative efforts have been so successful and have received such wide-spread community support that our CCOP was a model used as the basis for a successful Stage II Community Program for Clinical Research in AIDS.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045377-06
Application #
3558567
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1987-08-28
Project End
1994-05-31
Budget Start
1992-06-12
Budget End
1993-05-31
Support Year
6
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Providence Portland Medical Center
Department
Type
DUNS #
City
Portland
State
OR
Country
United States
Zip Code
97213
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10

Showing the most recent 10 out of 142 publications